Literature DB >> 11415859

Increased glucose-dependent insulinotropic polypeptide (GIP) secretion in acromegaly.

M Peracchi1, S Porretti, C Gebbia, C Pagliari, P Bucciarelli, P Epaminonda, S Manenti, M Arosio.   

Abstract

OBJECTIVE: Acromegaly is often associated with fasting and postprandial hyperinsulinemia, and the mechanisms involved are only partly understood. Hypersecretion of incretins such as glucose-dependent insulinotropic polypeptide (GIP) could play a role in determining hyperinsulinemia in acromegaly, but the available data are inconsistent. The aim of this study was to characterize the fasting and postprandial pattern of plasma GIP and insulin in a group of acromegalic patients. DESIGN AND METHODS: Eleven non-diabetic patients with newly diagnosed acromegaly and 11 sex- and age-matched healthy subjects were studied. Blood samples were taken at regular intervals in fasting conditions and for 3 h after a standard solid-liquid meal for growth hormone (GH), GIP and insulin measurements.
RESULTS: Not only insulin, but also fasting and postprandial GIP levels were significantly higher in the patients with acromegaly than the healthy subjects (P<0.01). In the former group fasting GIP levels and the integrated GIP response to the meal correlated significantly with GH basal levels (r=0.83, P<0.01 and r=0.65, P<0.05, respectively). Moreover, multivariate linear regression analysis showed that the presence of acromegalic status was associated with higher fasting and postprandial GIP levels independently of sex, age, fasting and postprandial plasma glucose and insulin levels, and the occurrence of normal or impaired glucose tolerance.
CONCLUSION: This study provides evidence that in patients with acromegaly fasting and postprandial GIP levels are abnormally high. GIP hypersecretion in turn might play a role in the pathogenesis of hyperinsulinemia that characterizes acromegaly.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11415859     DOI: 10.1530/eje.0.145r001

Source DB:  PubMed          Journal:  Eur J Endocrinol        ISSN: 0804-4643            Impact factor:   6.664


  6 in total

Review 1.  The pathogenic role of the GIP/GIPR axis in human endocrine tumors: emerging clinical mechanisms beyond diabetes.

Authors:  Daniela Regazzo; Mattia Barbot; Carla Scaroni; Nora Albiger; Gianluca Occhi
Journal:  Rev Endocr Metab Disord       Date:  2020-03       Impact factor: 6.514

2.  Characterization of sporadic somatotropinomas with high GIP receptor expression.

Authors:  Olivia Faria; Renan Lyra Miranda; Carlos Henrique de Azeredo Lima; Alexandro Guterres; Nina Ventura; Monique Alvares Barbosa; Aline Helen da Silva Camacho; Elisa Baranski Lamback; Felipe Andreiuolo; Leila Chimelli; Leandro Kasuki; Mônica R Gadelha
Journal:  Pituitary       Date:  2022-09-06       Impact factor: 3.599

3.  Elevated circulating somatostatin levels in acromegaly.

Authors:  M Arosio; S Porretti; P Epaminonda; C Giavoli; C Gebbia; C Penati; P Beck-Peccoz; M Peracchi
Journal:  J Endocrinol Invest       Date:  2003-06       Impact factor: 4.256

4.  Glucose-dependent Insulinotropic Polypeptide (GIP) Resistance and β-cell Dysfunction Contribute to Hyperglycaemia in Acromegaly.

Authors:  Vikram Singh Shekhawat; Shobhit Bhansali; Pinaki Dutta; Kanchan Kumar Mukherjee; Kim Vaiphei; Rakesh Kochhar; Saroj K Sinha; Naresh Sachdeva; Anura V Kurpad; Kishor Bhat; Sunder Mudaliar; Anil Bhansali
Journal:  Sci Rep       Date:  2019-04-04       Impact factor: 4.379

Review 5.  Insulin Resistance in Patients With Acromegaly.

Authors:  Greisa Vila; Jens Otto L Jørgensen; Anton Luger; Günter K Stalla
Journal:  Front Endocrinol (Lausanne)       Date:  2019-07-30       Impact factor: 5.555

6.  Prevalence of diabetes mellitus in patients with acromegaly.

Authors:  A V Dreval; I V Trigolosova; I V Misnikova; Y A Kovalyova; R S Tishenina; I A Barsukov; A V Vinogradova; B H R Wolffenbuttel
Journal:  Endocr Connect       Date:  2014-04-29       Impact factor: 3.335

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.